Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 1;9(12):1729-1733.
doi: 10.1001/jamaoncol.2023.4492.

Symptomatic Necrosis With Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain Metastases

Emily S Lebow  1   2 , Luke R G Pike  1 , Andrew D Seidman  3 , Nelson Moss  4 , Kathryn Beal  5 , Yao Yu  1
Affiliations

Symptomatic Necrosis With Antibody-Drug Conjugates and Concurrent Stereotactic Radiotherapy for Brain Metastases

Emily S Lebow et al. JAMA Oncol. .
No abstract available

Plain language summary

This cohort study investigates whether brain metastases that manifest after stereotactic radiotherapy with concurrent antibody-drug conjugates are associated with an increased risk of symptomatic radiation necrosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Pike reported receiving personal fees from Monograph Capital and Monte Rosa Therapeutics and grant funding from Caris Life Sciences and Delfi Diagnostics Inc, outside the submitted work; having equity or stock ownership in Schrödinger, Novavax, and Clovis Oncology; and receiving consulting and/or advisory fees from Blackstone Investments/Clarus Ventures, Third Rock Ventures, Deerfield Investments, Aviko Inc, Monograph Capital, Roivant Sciences Ltd, Galera Therapeutics, Dyno Therapeutics, Myst Therapeutics Inc, Monte Rosa Therapeutics, Best Doctors/Teladoc Health, and Turnstone Biologics Corp outside the submitted work. Dr Seidman reported receiving personal fees from Genentech Inc and AstraZeneca outside the submitted work; institutional research funding from Nektar Therapeutics, Odonate Therapeutics, and Bayer AG; and consulting and/or advisory fees from AstraZeneca, Genentech/Roche, Genomic Health, Gilead Sciences Inc/Forty Seven, Immunomedics, Eli Lilly and Company, Novartis AG, BeyondSpring Pharmaceuticals, Eisai Co Ltd, Gilead/Forty Seven, and Pfizer Inc. Dr Moss reported receiving consulting fees from AstraZeneca and institutional fees from AstraZeneca during the conduct of the study. Dr Yu reported receiving research funding (to Memorial Sloan Kettering Cancer Center) from EMD Serono Inc and royalties from Springer. No other disclosures were reported.

Figures

Figure.
Figure.. Incidence of Symptomatic Radiation Necrosis (SRN) for Brain Metastasis From the Start of Radiotherapy, Stratified by Receipt of Concurrent Antibody-Drug Conjugates (ADC)
Error bars indicate 95% CI point estimates at each time point.
See this image and copyright information in PMC

References

    1. Sneed PK, Mendez J, Vemer-van den Hoek JGM, et al. . Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. J Neurosurg. 2015;123(2):373-386. doi:10.3171/2014.10.JNS141610 - DOI - PubMed
    1. Montemurro F, Delaloge S, Barrios CH, et al. . Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann Oncol. 2020;31(10):1350-1358. doi:10.1016/j.annonc.2020.06.020 - DOI - PubMed
    1. Bartsch R, Berghoff AS, Furtner J, et al. . Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial. Nat Med. 2022;28(9):1840-1847. doi:10.1038/s41591-022-01935-8 - DOI - PMC - PubMed
    1. Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327-344. doi:10.1038/s41571-021-00470-8 - DOI - PMC - PubMed
    1. Zhou B, Fine J, Latouche A, Labopin M. Competing risks regression for clustered data. Biostatistics. 2012;13(3):371-383. doi:10.1093/biostatistics/kxr032 - DOI - PMC - PubMed

Substances